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Available online 26 October 2011The developing heart contains an inner tube of specialized endothelium known as endocardium, which per-
forms multiple essential functions. In spite of the essential role of the endocardium in heart development and
function, the transcriptional pathways that regulate its development remain largely undeﬁned. GATA4 is a
zinc ﬁnger transcription factor that is expressed in multiple cardiovascular lineages and is required for endo-
cardial cushion development and embryonic viability, but the transcriptional pathways upstream of Gata4 in
the endocardium and its derivatives in the endocardial cushions are unknown. Here, we describe a distal en-
hancer from the mouse Gata4 gene that is brieﬂy active in multiple cardiac lineages early in cardiac develop-
ment but restricts to the endocardium where it remains active through cardiogenesis. The activity of this
Gata4 cardiac enhancer in transgenic embryos and in cultured aortic endothelial cells is dependent on four
ETS sites. To identify which ETS transcription factors might be involved in Gata4 regulation via the ETS
sites in the enhancer, we determined the expression proﬁle of 24 distinct ETS factors in embryonic mouse
hearts. Among multiple ETS transcripts present, ETS1, FLI1, ETV1, ETV5, ERG, and ETV6 were the most abun-
dant in the early embryonic heart. We found that ETS1, FLI1, and ERG were strongly expressed in the heart at
embryonic day 8.5 and that ETS1 and ERG bound to the endogenous Gata4 enhancer in cultured endothelial
cells. Thus, these studies deﬁne the ETS expression proﬁle in the early embryonic heart and identify an ETS-
dependent enhancer from the Gata4 locus.
© 2011 Elsevier Inc. All rights reserved.Introduction
The embryonic cardiovascular system begins to assemble after
gastrulation around embryonic day (E) 7.5 in the mouse. Bilaterally
symmetrical mesodermal progenitors in the anterior lateral meso-
derm fuse at the midline to fashion a linear heart tube made up of
an outer layer of myocardial cells that surround an inner layer of en-
dothelial cells known as the endocardium (Brand, 2003). As the linear
heart tube forms, angioblasts in the lateral mesoderm differentiate
into endothelial cells and form the ﬁrst lumenized vessels in the em-
bryo (Flamme et al., 1997). As development proceeds, the heart un-
dergoes extensive morphogenesis, which ultimately separates the
right and left sides and inﬂow and outﬂow regions (Brand, 2003). In
parallel, the vasculature is elaborated, forming a complex network
of vessels to deliver blood and nutrients, pumped by the heart,
throughout the developing embryo (Drake and Fleming, 2000).
The endocardium is continuous with the vascular system but is
composed of specialized endothelial cells (Harris and Black, 2010).
Endocardial cells have distinct cytoskeletal and connective character-
istics compared to other types of endothelial cells (Andries and
Brutsaert, 1993; Brutsaert and Andries, 1992; Melax and Leeson,ular y Medicina Regenerativa
rights reserved.1967). During embryonic development, endocardial cells perform
unique roles in the developing heart: they induce some myocardial
cells to form essential trabeculae, ridges of myocardium within the
ventricles (Stankunas et al., 2008; Wagner and Siddiqui, 2007), and
a subset of specialized cells from the endocardium undergo
endocardial-to-mensenchymal transformation (EMT) to populate
the endocardial cushions, which give rise to the cardiac valves and
portions of the interventricular and atrial septa (Hutson and Kirby,
2007; Person et al., 2005; Snarr et al., 2008). The unique nature of
the endocardium may arise, at least in part, from signals received by
the endocardium during cardiogenesis, which are different than sig-
nals in other areas of endothelial speciﬁcation in the embryo
(Misfeldt et al., 2009). Importantly, malformations in the endocardi-
um and its derivatives underlie numerous pediatric and adult cardiac
diseases (Bruneau, 2008; Markwald et al., 2010). In spite of its role in
development and disease, molecular and genetic characteristics that
distinguish the endocardium from other endothelial cells remain in-
completely deﬁned, and the cell-autonomous transcriptional path-
ways important for endocardial development are poorly understood
(Harris and Black, 2010).
The ETS family of transcription factors is widely appreciated for its
role in endothelial cell development and function (De Val and Black,
2009; Hollenhorst et al., 2011; Sato, 2001). The ETS family is com-
posed of thirty factors in mammals. ETS proteins are deﬁned by the
presence of a conserved DNA-binding domain and a common consen-
sus target sequence, GGA(A/T) (Hollenhorst et al., 2011). Human
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Among them, ETS1, ETS2, FLI1, ETV2, and ETV6 are required for nor-
mal vascular development in mice (Barton et al., 1998; Lee et al.,
2008; Spyropoulos et al., 2000; Wang et al., 1997; Wei et al., 2009).
ETS factors regulate vascular development by binding consensus tar-
get sequences in many endothelial genes, such as Cdh5, Tie2, and Flk1,
which are important in differentiated endothelial cell function (De
Val and Black, 2009). In addition, ETS factors directly regulate other
transcription factor genes, suggesting ETS factors are important
nodes in transcriptional pathways that govern endothelial speciﬁca-
tion (De Val and Black, 2009; De Val et al., 2008; Pimanda et al.,
2007, 2008).
The GATA family of transcription factors participates in the tran-
scriptional pathways that regulate the development of several cardio-
vascular lineages, including the myocardium, epicardium, and
endocardial cushions (Lepore et al., 2006; Lugus et al., 2007; Rivera-
Feliciano et al., 2006; Rojas et al., 2008; Song et al., 2009; Xin et al.,
2006; Zeisberg et al., 2005; Zhao et al., 2008). The GATA family con-
sists of six factors that share a zinc-ﬁnger DNA-binding domain that
binds to the GATA consensus sequence, (A/T)GATA(A/G), which is
found in numerous cardiovascular gene regulatory regions (Charron
and Nemer, 1999; De Val and Black, 2009; Molkentin, 2000; Patient
and McGhee, 2002). GATA4 is a GATA transcription factor that is re-
quired for myocardial and endocardial development (Oka et al.,
2006; Rivera-Feliciano et al., 2006; Rojas et al., 2008; Zeisberg et al.,
2005). Gata4-null mice have defective endoderm development lead-
ing to cardia biﬁda (Kuo et al., 1997; Molkentin et al., 1997), and
mice lacking GATA4 in the myocardium display defective cardiomyo-
cyte proliferation and embryonic lethality (Rojas et al., 2008; Zeisberg
et al., 2005). Mice lacking Gata4 in the endothelium have defective
endocardial cushion development and die around E12.5 of apparent
heart failure (Rivera-Feliciano et al., 2006). In spite of its importance
in heart development, the transcriptional pathways upstream of
Gata4 in cardiovascular development are unknown.
In this study, we identify a distal enhancer of the mouse Gata4
gene. This enhancer, referred to as Gata4 G9, is active in the cardiac
crescent at E7.5 and in the linear heart at E8.5. As the heart undergoes
looping morphogenesis, enhancer activity remains strong in the en-
docardial layer but rapidly diminishes in the myocardial layer. At
E11.5 and later stages, the enhancer is active only in the endocardium
and its derivatives in the endocardial cushions. We deﬁne a minimal
region of the enhancer that is necessary and sufﬁcient for endocardial
activity in transgenic mouse embryos and in cultured aortic endothe-
lial cells. We show that the enhancer is dependent on four consensus
ETS binding sites, since mutation of the sites completely abrogates
enhancer activity in vivo. To determine which ETS factors regulate
Gata4 via the ETS sites in the enhancer, we assessed the expression
of twenty-four ETS factors in the embryonic heart. Among these fac-
tors, transcripts for FLI1, ETV5, ETV6, ETS1 ERG, ELF1, ETV1, and
ETS2 were the most enriched, and ETS1 and ERG bound to the endog-
enous Gata4 G9 enhancer in cultured aortic endothelial cells as deter-
mined by chromatin immunoprecipitation. Thus, these studies deﬁne
the ETS expression proﬁle in the early embryonic heart, and identify a
cardiac enhancer from the Gata4 locus that is active predominately in
the endocardium and is directly regulated by ETS proteins.
Materials and methods
Bioinformatic analyses, cloning, and mutagenesis
Mouse, human, and cow sequences were compared using BLAST
and VISTA (Altschul et al., 1990; Mayor et al., 2000). The 1945-bp
Gata4 G9 fragment was generated by PCR from mouse genomic
DNA using the following primers: 5′-gctggacctgtctcgagcacacttgttat-
3′ and 5′-tctcagaataacccgggatgactattt-3′. The 404-bp Gata4 G9
[902–1305] fragment was generated from Gata4 G9 using thefollowing primers: 5′-ggcgtttctcgagtagtccttggatgccagaa-3′ and 5′-
ataatcacccgggcctgttgccctccgccct-3′. The deletion construct Gata4 G9
[Δ902–1305] was generated by PCR from Gata4 G9 using the follow-
ing mutagenic primer and its reverse complement: 5′-gctctgagggacg-
caggggatccagtgagc-3′. All Gata4 G9 fragments were cloned into the
XhoI–XmaI sites of the transgenic reporter plasmid hsp68-lacZ
(Kothary et al., 1989). The 4× ETS mutant was generated by PCR
using the following mutagenic primers and their reverse comple-
ments: ETS-E mutant, 5′-ttctgataaatgggttgctccacccctccc-3′, ETS-H
mutant, 5′-ctcagactgatgggcaataccattgtctg-3′, and ETS-I/J mutant, 5′-
ccagggcgacaggcattgcagaggcgtgggg-3′.
Generation of transgenic mice
Transgenic lacZ reporter fragments were generated by gel purify-
ing Xho–SalI fragments from parental hsp68-lacZ plasmids. Pronu-
clear injection of transgene fragments was performed as described
previously (Dodou et al., 2004). The presence of lacZ transgenes in
embryo yolks sacs or tail biopsies was detected using PCR and
primers speciﬁc for the transgene or by Southern blot using a probe
speciﬁc for lacZ. All experiments using animals were reviewed and
approved by the UCSF Institutional Animal Care and Use Committee
and complied with all institutional and federal guidelines.
X-gal staining, immunoﬂuorescence, and immunohistochemistry
β-galactosidase activity in transgene-positive embryos was
detected by X-gal staining, as described previously (Anderson et al.,
2004). Transverse sections from X-gal stained embryos were pre-
pared and counterstained with Neutral Fast Red as described previ-
ously (Dodou et al., 2003). For section immunoﬂuorescence and
immunohistochemistry, embryos were sectioned, de-waxed, boiled
in antigen retrieval solution (Biogenex), and blocked in PBS contain-
ing 10% sheep serum and 0.1% Triton X-100. For whole mount immu-
nohistochemistry, embryos were boiled in antigen retrieval solution
(Biogenex), treated with 5% H2O2, and blocked in PBS with 5% milk,
5% sheep serum, and 0.1% Triton X-100. The following primary
antibodies were used at 1:100 dilutions in blocking serum: rabbit
anti-ETS1 (Santa Cruz; sc-350), mouse anti-GABPA (Santa Cruz; sc-
28311), rabbit anti-FLI1 (Santa Cruz; sc-356), rabbit anti-ERG1/2/3
(Santa Cruz; sc-353), rabbit anti-ETV6 (Santa Cruz; sc-11382), mouse
anti-myosin heavy chain (DHSB; MF20), mouse anti-GATA4 (Santa
Cruz; sc-25310), chicken anti-β-galactosidase (Abcam; Ab9361), and
rat anti-endomucin (eBioscience; 14-5851-82). The following second-
ary antibodies were used at 1:300 dilutions in blocking serum: biotiny-
lated goat anti-rabbit IgG (Vector Laboratories; BA-1000), biotinylated
goat anti-mouse IgG (Vector Laboratories; BA-9200), Alexa Fluor 594
goat anti-chicken IgG (Invitrogen; A11042), streptavidin Alexa Fluor
488 (Invitrogen; S32354), and Oregon Green anti-mouse IgG (Invitro-
gen; O-6383). For immunoﬂuorescence, slides were mounted and
photographed as described previously (Rojas et al., 2009). For immuno-
histochemistry, immunoperoxidase staining and photography were
performed as described previously (Rojas et al., 2009).
Cell Culture, transfections, and reporter assays
For transfection experiments, full-length Gata4 G9, G9[902–1305],
and mutant constructs were subcloned from hsp68-lacZ as KpnI frag-
ments into the KpnI site of a modiﬁed pGL2-Basic vector (Promega)
that contains the thymidine kinase (TK) minimal promoter. Bovine
aortic endothelial cells (BAEC) were purchased from Cambrex Bio
and maintained in Dulbecco modiﬁed Eagle medium supplemented
with 10% fetal bovine serum, 1% L-glutamine and 1% Penicillin/Strep-
tomycin. Transient transfections were performed in 24-well plates
using Lipofectamine LTX (Invitrogen) following the manufacturer's
recommendations. Transfection mixtures contained 0.4 μg of reporter
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tein concentration, 48 h after transfection, using the Luciferase Assay
System (Promega) according to the manufacturer's protocol.
cDNA preparation and quantitative real time PCR
Embryos were collected between 8.5 and 9.5 days post-coitum
and hearts were mechanically dissected and pooled. RNA was
extracted using the Qiagen RNeasy Micro Kit, as recommended by
the manufacturer. RNA was then used to generate cDNA with the
SuperArray RT2 First Strand Kit according to the manufacturer's
directions.
Quantitative real time PCR (qPCR) was performed using SYBR
Green PCR Master Mix (Applied Biosystems) and primers that have
been previously described (Galang et al., 2004). The reaction mix-
tures were analyzed on an Applied Biosystems 7900HT Fast Real
Time PCR System. Analysis of relative gene expression was performed
as previously described (Galang et al., 2004). Brieﬂy, for each experi-
ment, a standard curve relating GAPDH cDNA concentration to thresh-
old cycle (Ct) was generated using serial dilutions of cDNA with
GAPDH primers. cDNA concentration was calculated according to the
standard curve and then normalized to the GAPDH concentration.
Electrophoretic mobility shift assay (EMSA)
DNA binding assays were performed as described previously
(Dodou et al., 2003) in modiﬁed 1× binding buffer (15 mM KCl,
5 mM Hepes pH 7.9, 5% glycerol, 0.04 mM EDTA, 0.125 mM DTT,
0.25 mM PMSF). The ETS1 DNA-binding domain (DBD) construct
used in EMSA analyses has been described previously (De Val et
al., 2004). The ETS1 DBD was transcribed and translated using the
TNT Coupled Transcription–Translation system (Promega) accord-
ing to the manufacturer's protocol. The ETS1 control (Mef2c-F7
ETS-A) and mutant control probe sequences have been described
previously (De Val et al., 2004) and were: control, 5′-gctcagagaag-
gaagtggagagt-3′; mutant, 5′-gctcagagaagcttgtgggaggtt-3′. The se-
quences of the competitor oligonucleotides encompassing the ETS sites
from the Gata4 G9 enhancer were: ETS-A, 5′-tagtccttggatgccagaaagaaa-
3′; ETS-B, 5′-agaaagaaaggccaggaattgtggc-3′; ETS-C, 5′-ccagctgttagggg-
gaacggggtgaattct-3′; ETS-D, 5′-ccagctgttaagggggaacggggtgaattct-3′ ETS-
E, 5′-ttctgataaatgggttcctccacccctccc-3′; ETS-F, 5′-cccggtgcagaaaccacttc-
caagccaggcatga-3′; ETS-G, 5′-aaaaacagcagtggataaggcccgg-3′; ETS-H, 5′-
ctcagactgatgggaaataccattgtctg-3′, ETS-I/J, C 5′-ccagggcgacagggattcca-
gaggcgtgggg-3′. The sequences for the ETS mutant sites were identical
to the mutagenic primers described above.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using the ChIP Assay Kit (Millipore;
17-295). DNA was isolated from conﬂuent BAEC grown on 10 cm
plates. Chromatin derived from 1×106 cells was cross-linked, lysed,
and sonicated to shear the DNA into 200–500 bp fragments. Samples
were pre-cleared and incubated with antibody. Normal rabbit IgG
(Santa Cruz; sc-2027), rabbit anti-ETS1 (Santa Cruz; sc-350), andFig.1. Schematic representation of the mouse Gata4 locus and the Gata4-G9-LacZ transgene
represent exons in the locus. The red boxes represent non-coding regions of deep conserva
cloned into the hsp68-lacZ transgenic reporter (lower schematic).rabbit anti-ERG1/2/3 (Santa Cruz; sc-353) were used at a concentra-
tion of 1 μg/ml. After incubation with protein-A-agarose beads, sam-
ples were washed and protein-DNA complexes were eluted. The
crosslinks were reversed and the DNA was recovered by phenol–chlo-
roform extraction. The primers used to amplify the region of the bovine
Gata4 G9 enhancer containing the ETS sites were 5′-gacaatgggtgttagac-
taatag-3′ and 5′-gcttgtggccgctgggatccctgtcgc-3′. The primers used to
amplify a non-conserved sequence of Gata4 outside the G9 en-
hancer region were 5′-ttagagggctacagtccatacg-3′ and 5′-agattaat-
cagactcatctggcc-3′.Results
Identiﬁcation of a Gata4 enhancer with activity in the developing heart
To identify enhancers of Gata4 expression, we screened nine re-
gions of conserved noncoding sequence from the Gata4 locus for en-
hancer activity in transgenic mice (Fig. 1). Multiple enhancers were
identiﬁed. Two enhancers (G4 and G8) have early- and late-acting en-
doderm speciﬁcities (Rojas et al., 2009, 2010). A third enhancer (G2)
directs activity to the lateral mesoderm and its derivatives in the liver
mesenchyme (Rojas et al., 2005). The most distal region that we tested
spans 1945 bp and is located approximately 93 kb away from the Gata4
transcriptional start site (Fig. 1). We cloned this region, referred to as
Gata4 G9, into the transgenic reporter plasmid Hsp68-lacZ (Kothary et
al., 1989) and assayed β-galactosidase reporter activity by X-gal stain-
ing of transgenic embryos (Fig. 2). At E7.5, enhancer activity was ob-
served in the embryo in a crescent-shaped region of splanchnic
mesoderm corresponding to the developing heart ﬁeld (Fig. 2A). The
expression pattern of GATA4 protein at the same embryonic stage
was similar because it included the crescent-shaped region of precar-
diac mesoderm marked by the Gata4-G9-lacZ transgene but was also
broader because GATA4 protein was detected in the lateral mesoderm
(LM) (Fig. 2C). This was expected since endogenous GATA4 is
expressed in multiple lineages in addition to the heart (Arceci et al.,
1993; Molkentin, 2000).
Detailed analyses of transverse sections showed X-gal staining in
the precardiac mesoderm and allantois at E7.5 (Fig. 2B). At E8.5, the
Gata4 G9 enhancer was active in the linear heart tube and allantois
(Figs. 2D, E) in a pattern similar to endogenous GATA4 expression
(Fig. 2F). Transverse sections through the hearts of transgenic lines
with enhancer activity revealed that the majority (9/12) of Gata4-
G9-lacZ lines had activity restricted to the endocardium at E8.5 with
at most, a few cells stained in the myocardium (Fig. 2G). However, a
minority of the lines (3/12) with strong expression of β-galactosidase
in the endocardium also exhibited X-gal staining in the myocardium
at E8.5 (Fig. 2H). Importantly, the expression of β-galactosidase from
weak and strong lines overlapped with a subset of the endogenous
GATA4 expression pattern in the heart, as determined by anti-β-
galactosidase and anti-GATA4 immunoﬂuorescence (Fig. 2I). Three
transgenic lines displayed no activity in the heart or elsewhere at this
stage, probably due to insertion into inactive regions in chromatin
(data not shown).. The black horizontal line represents the mouse Gata4 locus and the black vertical bars
tion between mouse, human, and opossum. A 1945-bp region, encompassing G9, was
Fig. 2. The Gata4 G9 enhancer is active in cardiac progenitors in the cardiac crescent
and the linear heart tube and restricts to endocardium during mouse cardiogenesis.
X-gal stained embryos photographed as whole-mounts (A, D, E, J, K, P) or following
transverse sectioning of stained embryos (B, G, H, M, N, Q) are shown. For comparison,
wild type embryos stained as whole mounts with anti-GATA4 antibody are shown (C, F,
L). In addition, transverse frozen sections stained for immunoﬂuorescence with anti-β-
galactosidase and anti-GATA4 antibodies are also shown (I, O, R). Strong Gata4-G9-lacZ
transgenic lines are pictured in B, E, H, I, K, N, and O; weak Gata4-G9-lacZ lines are pic-
tured in D, G, J, M. Asterisks mark endocardium and arrowheads mark myocardium. al,
allantois; EC, endocardial cushions; hrt, heart; LM, lateral mesoderm; LV, left ventricle;
PCM, precardiac mesoderm; RV, right ventricle; ST, septum transversum. Bars in all
panels=100 μM.
Fig. 3. The Gata4 G9 enhancer is active in the endocardium andmyocardium of the linear
heart. Sections from a strong transgenic Gata4-G9-lacZ embryo at E8.5 were stained with
anti-β-galactosidase (A, A″, B, B″), anti-endomucin (A, A′), and anti-myosin heavy chain
(MyHC) (B, B′) antibodies. The Gata4 G9 enhancer directed β-galactosidase expression
throughout the endocardium (asterisks). A minority of cells in the myocardial layer also
showed anti-β-galactosidase staining (arrowheads). Merged images show endomucin-
β-galactosidase-double-positive orange cells (A) and MyHC-β-galactosidase-double-
positive orange cells (B). Note that there are no β-galactosidase-negative endocardial
cells at this stage (A), that there are endomucin-positive but β-galactosidase-negative en-
dothelial cells in the dorsal aorta (DA), and that the majority of the MyHC-positive cells
are β-galactosidase-negative (B″). Bars in all panels=100 μM.
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present in both the endocardial and myocardial layers of the heart
at E8.5 (Figs. 2E, H), we compared the expression of β-galactosidasefrom Gata4-G9-lacZ transgenic embryos to endothelial and myocardi-
al markers at this stage (Fig. 3). β-galactosidase expression complete-
ly overlapped with the expression of the endothelial marker
endomucin within the endocardium at E8.5 (Fig. 3A). As noted
above, in the majority of transgenic lines examined at E8.5, transgene
activity was mostly restricted to the endocardium (Figs. 2D, G). How-
ever, in lines with the strongest X-gal staining, the expression of β-
galactosidase also overlapped with the expression of myosin heavy
chain in some, but not all, cells of the myocardium (Fig. 3B). Thus,
the Gata4 G9 enhancer is active in presumptive endocardial and myo-
cardial progenitors in precardiac mesoderm at E7.5 and is active
throughout the endocardium at E8.5. The enhancer also has weak
and incomplete activity in the myocardium, which is only apparent in
the strongest transgenic lines.
At E9.5, Gata4-G9-lacZ transgene expression was restricted to the
endocardium of the looping heart and to the endothelium of the
proximal outﬂow tract in the majority of the independent transgenic
lines with enhancer activity (7/11) (Figs. 2J, M). However, as was the
case at E8.5, X-gal staining in myocardial cells could be detected in
the strongest lines at E9.5 (4/11) (Figs. 2K, N). In these strong lines,
X-gal activity was more restricted within the myocardium compared
to E8.5, suggesting further restriction to the endocardium (Fig. 2,
compare panels H and N). The pattern of transgene activity in the
heart, even in the strongest lines, was more restricted than endoge-
nous GATA4 (Figs. 2J, L, O). Endogenous GATA4 protein was detect-
able in the septum transversum and developing gut at this stage
(2L), but neither the weak nor strong lines displayed X-gal staining
in either of those tissues (2J,K). Thus, Gata4 G9 enhancer activity
marks a restricted subset of the broader endogenous GATA4 expres-
sion pattern.
By E11.5, Gata4-G9-lacZ enhancer activity was restricted to the en-
docardial cell layer of the developing heart in all lines examined and
activity was never observed in the myocardium (Figs. 2P, Q). We also
observed robust enhancer activity in the mesenchymal cells populating
the proximal outﬂow tract and atrioventricular endocardial cushions
(Fig. 2Q). The staining of these cells likely reﬂects their endocardial or-
igin since they are derived primarily from endothelial cells overlying
the cushions that have undergone endothelial-to-mesenchymal transi-
tion (Combs and Yutzey, 2009). We cannot rule out the possibility that
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origin, but we consider this unlikely since enhancer activity was
never observed in the cardiac neural crest itself. As in earlier stages,
β-galactosidase-positive cells overlapped with a subset of endogenous
GATA4 (Fig. 2R). At later stages of embryonic development and in neo-
natal mice, Gata4-G9-lacZ transgene expression was detected in the
outﬂow tract endocardium and in the aortic endothelium in some
lines (data not shown). Thus, while the enhancer is strongly active in
endocardial cells and weakly in myocardial cells when the linear
heart ﬁrst appears, its activity remains strong only in the endocardium
and its derivatives in the endocardial cushions at subsequent stages.
Importantly, this dynamic enhancer activity occurs within the broader
endogenous GATA4 expression pattern. These results, and the location
of the enhancer proximal to the Gata4 locus, suggest the Gata4 G9 en-
hancer is indeed a bona ﬁde enhancer of mouse Gata4 transcription.
A 404-bp fragment of Gata4 G9 is necessary and sufﬁcient for enhancer
activity in vivo
To delimit the essential transcription factor binding elements within
the Gata4 G9 fragment, we wanted to deﬁne a minimal region neces-
sary and sufﬁcient for cardiac activity in embryos. Comparison of
mouse, human, and bovine Gata4 sequence revealed one 404-bp
evolutionarily-conserved region (ECR), spanning base pairs 902–1305,
within the 1945-bp Gata4 G9 enhancer (Fig. 4A). To determine whether
this regionwas necessary and sufﬁcient for enhancer activity in vivo, we
tested deletion constructs of Gata4-G9-lacZ for activity in transgenic
mouse embryos (Figs. 4A–D). The evolutionarily conserved 404 bp re-
gion directed activity to the heart at E8.5 in a pattern similar to the
full-length 1945-bp enhancer (Fig. 4, compare panels B and D), indicat-
ing that the ECR was sufﬁcient for Gata4 G9 enhancer activity in theFig. 4. The Gata4 G9 enhancer contains a deeply conserved region that is necessary and sufﬁ
lines represent the Gata4 G9 enhancer and deletion mutants. The blue box between positions
right indicates the number of independent transgenic lines that expressed β-galactosidase i
Representative transgenic embryos collected at 8.5 days post-coitum from the three constr
sections through the heart from three distinct embryos from those shown in B, C, and D are
cardium. al, allantois; hrt, heart. (E) BAEC were transfected with TK-luciferase, full-lengt
[902–1305]-TK-luciferase reporters. The activity of the Gata4 G9[1–1945] enhancer was
1305] construct was inactive (lanes 1–3). The construct containing Gata4 G9[902–1305]
mean fold activation over TK-luciferase. Error bars represent SEM for 8 independent transfheart and allantois. As with the full-length construct, a majority of the
lines in which the transgene was active exhibited X-gal activity mainly
in the endocardium. The ECR was also required for enhancer activity in
vivo, as evidenced by the inactivity of the Gata4 G9 enhancer transgene
in which the conserved region was deleted (Fig. 4C).
We also tested the activity of the full-length Gata4 G9 enhancer,
the 902–1305 sufﬁciency region, and the Δ902–1305 fragment in bo-
vine aortic endothelial cells (BAEC) (Fig. 4E). Bovine aortic endotheli-
al cells (BAEC) are a well-established endothelial system (Gory et al.,
1998; Ronicke et al., 1996; Schlaeger et al., 1997), and we reasoned
that because the Gata4 G9 enhancer was active in endocardial endo-
thelium and in the proximal aortic and outﬂow tract endothelium in
transgenic mice, BAEC would serve as a relevant cell culture system
to further characterize enhancer function, particularly since there
are no established endocardial cell lines. The full-length and minimal
404-bp Gata4 G9 enhancer fragments directed robust and signiﬁcant
reporter activity in BAEC compared to the parental TK vector
(Fig. 4E). Interestingly, the ECR was more active than the full-length
fragment, suggesting elements outside of the minimal region might
repress activity in cultured cells. However, in the developing embryo,
these putative repressor elements appear to play no role, as the min-
imal region did not direct activity outside of the tissues in which the
full-length enhancer was active (4B,D). Alternatively, the smaller
404-bp fragment might position critical regulatory elements closer
to the promoter than the full-length, 1945-bp fragment, allowing
for more potent activation in cultured cells. Importantly, the mutated
enhancer (Δ902–1305), in which the ECR was deleted, displayed only
background activation in BAEC (Fig. 4E). These cell culture experi-
ments were consistent with the in vivo data in transgenic mouse em-
bryos and establish that Gata4 G9[902–1305] contains elements that
are necessary and sufﬁcient for enhancer activity in the heart,cient for activity in vivo and in cultured aortic endothelial cells. (A) The black horizontal
902 and 1305 represents the evolutionarily conserved region (ECR). The column to the
n the endocardium at E8.5 over the total number of transgene-positive embryos. (B–D)
ucts tested. Whole mount X-gal-stained embryos are shown in B, C, and D. Transverse
shown in B′, C′, and D′. Asterisks mark the endocardium. Arrowheads mark the myo-
h Gata4-G9[1–1945]-TK-luciferase, Gata4-G9[Δ902–1305]-TK-luciferase, or Gata4-G9
approximately 7-fold higher than the parental TK vector while the Gata4 G9[Δ902–
showed 53-fold more activity compared to the parent vector. Data are shown as the
ections and analyses. Indicated p values were calculated by two-tailed, unpaired t test.
444 W. Schachterle et al. / Developmental Biology 361 (2012) 439–449including the endocardium, and aortic endothelium in vivo and in cul-
tured aortic endothelial cells.
The Gata4 G9 enhancer contains four ETS sites essential for
enhancer function
Among multiple potential candidate sites within the 404-bp con-
served region of Gata4 G9, we identiﬁed ten consensus ETS binding
sites in the mouse sequence (Fig. 5A; ETS sites A–J). The presence of
multiple ETS sites was intriguing since several ETS transcription fac-
tor family members are well-established essential regulators of endo-
thelial development (De Val and Black, 2009; Graves and Petersen,
1998). To determine which of the consensus ETS elements within
the 404-bp region of the Gata4 G9 enhancer function as bona ﬁde
ETS transcription factor binding sites, we designed probes encom-
passing each of the ten consensus ETS elements and tested their abil-
ity to compete for the binding of the ETS1 DNA-binding domain
(DBD) to a bona ﬁde control ETS site. We used the ETS1 DBD as a gen-
eral ETS domain because ETS1 binding has been well characterized
and because all ETS transcription factors share this highly conserved
motif (Graves and Petersen, 1998; Hollenhorst et al., 2011). As
expected, ETS1 efﬁciently bound to a radiolabeled probed encompass-
ing the bona ﬁde control ETS site (Fig. 5B, Lane 2), and excess unlabeled
control probe competed for binding (Fig. 5B, Lane 3). Each of the Gata4
G9 probes containing ETS consensus elements competed for ETS1 DBDFig. 5. The Gata4 G9 enhancer contains ETS binding sites. (A) ClustalW analysis of the 404-b
10 ETS consensus sequences (gray boxes). (B) Recombinant ETS1 DNA-binding domain (DBD
from theMef2c locus. Lanes 1 and 13 contain unprogrammed rabbit reticulocyte lysate. ETS1
this speciﬁc binding was competed by unlabeled control probe (lanes 3, 15). Unlabeled prob
for ETS1 DBD binding to the control probe (lanes 4–12). The Gata4 G9 ETS sites competed
(lanes 8, 11, and 12), and were further examined for competition with the control prob
binding consensus sequences in ETS-E, H, and I/J reduced competition compared to wild tybinding to the control probe to some extent, although most competed
only weakly (Fig. 5B, lanes 4–12). Among the ten Gata4 G9 ETS site
probes, ETS-E, ETS-H, and ETS-I/J competed most effectively (Fig. 5B,
Lanes 8, 11, 12). The binding of the ETS1 DBD to the ETS-E, ETS-H,
and ETS-I/J sites was speciﬁc since competitor probes with mutations
in each of those ETS sites abolished competition for binding to the con-
trol probe (Fig. 5B, lanes 17–22). These results demonstrate that the
Gata4 G9 ECR contains several ETS sites capable of ETS protein binding
and that ETS-E, ETS-H, and ETS-I/J are the sites with the highest afﬁnity
for ETS1 in vitro.
To examine the Gata4 G9 ETS sites for functionality in vivo, we gen-
erated transgenic mice bearing the minimal Gata4-G9[902–1305]-lacZ
transgene in which the ETS-E, ETS-H, and ETS-I/J sites were mutated
and compared transgene activity of the mutant construct to a wild
type Gata4-G9[902–1305]-lacZ transgene (Figs. 6A, B). As expected,
Gata4-G9[902–1305] directed β-galactosidase activity to the develop-
ing heart at E8.5 (Fig. 6A). In contrast, mutation of the four ETS binding
sites completely abolished enhancer activity (Fig. 6B), indicating that
the four most robust in vitro-binding ETS sites are required for Gata4
G9 enhancer function in vivo. Consistent with this observation, muta-
tion of the same four ETS sites resulted in a signiﬁcant reduction of en-
hancer activity in BAEC compared to the wild type construct (Fig. 6C).
Thus, these results establish that Gata4 G9 cardiac enhancer is a direct
transcriptional target of ETS factors in vivo and in cultured endothelial
cells.p Gata4 G9 ECR, comparing mouse, human, and bovine sequences. The region contains
) was used in EMSA with radiolabeled probe encompassing a bona ﬁde ETS-binding site
DBD bound to the bona ﬁde ETS-binding site in the control probe (lanes 2, and 14) and
es corresponding to each of the ETS sites in the Gata4 G9 ECR were used as competitors
to varying degrees. Probes encompassing ETS-E, -H, and -I/J competed most efﬁciently
e using wild type and mutant versions of each (lanes 17–22). Mutation of the ETS-
pe sequences (compare lanes 17–18, 19–20, and 21–22).
Fig. 6. Gata4 G9 enhancer activity is dependent on four ETS sites. (A, B) Representative
transgenic embryos harboring Gata4-G9[902–1305]-lacZ and Gata4-G9[902–1305] 4×
ETS mutant-lacZ transgenes are shown. 6 of 8 independently generated Gata4-G9
[902–1305]-lacZ transgenic lines showed the pattern shown in (A). No activity of the
4× ETS mutant transgene was observed in any of the 6 independent lines examined.
(C) BAEC were transfected with TK-luciferase, Gata4-G9[902–1305]-TK-luciferase, or
G9[902–1305] 4× ETS mutant-TK-luciferase, and activity was determined. The activity
of Gata4-G9[902–1305] was approximately 73-fold higher than the parent TK reporter
(lanes 1, 2). Mutation of the 4 ETS sites (ETS-E, ETS-H, and ETS-I/J) reduced activity by
approximately 65% compared to Gata4-G9[902–1305]-TK-luciferase. Data are shown as
the mean fold activation over TK-luciferase control. Error bars represent SEM for 13 in-
dependent transfections and analyses. Indicated p values were calculated by two-
tailed, unpaired t test.
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The ETS family contains more than thirty members, all of which
contain a DNA-binding domain that speciﬁcally binds to a GGA(A/T)
motif in target enhancers, such as those identiﬁed in the Gata4 G9 en-
hancer. Expression analyses have shown 19 ETS factors are expressed
in endothelial cells and 20 ETS factors are expressed in the adult heart
(Hollenhorst et al., 2004). Thus, a large number of ETS factors could
potentially bind the candidate ETS sites in the Gata4 G9 enhancer.
As a ﬁrst step to determine the ETS factors that are the most highly
expressed in the developing heart when the Gata4 G9 enhancer is ac-
tive, we performed qPCR using validated primers designed to exam-
ine mRNA expression of 24 unique ETS genes in dissected hearts
and associated tissues at E8.5 (Fig. 7A). Transcripts for multiple ETS
factors were detected by qPCR, which showed that the most abun-
dant ETS transcripts in the early embryonic mouse heart were
GABPA, FLI1, ETV5, ETV6, ETS1, ERG, ELF1, ETV1, and ETS2 (Fig. 7A).
Among those ETS genes expressed in the early heart, several are
known to be required for embryonic development and endothelial
gene expression. Gabpa, Ets1, Ets2, Fli1, Etv6, and Erg are essential
for embryonic development and regulate endothelial gene expression
(De Val and Black, 2009; Loughran et al., 2008; Ristevski et al., 2004;
Spyropoulos et al., 2000; Wang et al., 1997; Wei et al., 2009). By con-
trast, Etv5-, Etv1-, and Elf1-null mice have apparently normalendothelial development and are viable (Arber et al., 2000;
Garrett-Sinha et al., 2001; Hippenmeyer et al., 2007). Because
Gata4 is also required in the endothelium for normal endocardial de-
velopment and embryonic viability (Rivera-Feliciano et al., 2006), we
further analyzed by immunohistochemistry the expression patterns
of those ETS proteins that were abundantly expressed in the early
heart and that also play essential roles in development (Figs. 7B–F).
We analyzed the expression patterns of ETS1, FLI1, ERG, GABPA,
and ETV6 by immunohistochemistry to determine whether the ex-
pression of those ETS proteins overlapped with Gata4 G9 enhancer
activity at E8.5. ETS1, FLI1, and ERG were expressed in the endocardi-
um at E8.5 (Figs. 7B–D). ETS1 and FLI1 were also strongly expressed
in the myocardium, whereas ERG was not readily detected in the
myocardium at this stage (Figs. 7B–D). GABPA and ETV6 were not
strongly expressed in the endocardium (Figs. 7E, F). The apparent
abundance of GABPA as determined by qPCR might have been the re-
sult of strong expression in the neighboring foregut (Fig. 7E), which
may have been inadvertently included when embryonic hearts were
isolated. Alternatively, this may reﬂect a discrepancy between
GABPA RNA and protein expression. The abundance of ETV6 in the
early embryonic heart by PCR was likely the result of strong expres-
sion in the myocardium rather than expression in the endocardium,
which was undetectable by immunohistochemistry at E8.5 (Fig. 7F).
Because the Gata4 G9 enhancer is active primarily in the endocardi-
um at E8.5 (Figs. 2, 3), we reasoned that ETS factors present through-
out the endocardium could be potential regulators of the enhancer.
The data in Fig. 7 show that ETS1, FLI1, and ERG protein expression
correlated with Gata4 G9 enhancer activity in the endocardium,
therefore, we pursued these factors as potential direct regulators of
the Gata4 G9 enhancer.
ETS1 and ERG occupy the endogenous Gata4 G9 enhancer
To determine if ETS1, FLI1, and ERG occupied the ETS sites in the en-
dogenous Gata4 G9 enhancer in endothelial cells, we performed ChIP
assays in BAEC (Fig. 8). Binding of FLI1 to the endogenous enhancer
was not reproducibly detected (data not shown). However, anti-ETS1
and anti-ERG antibodies consistently immunoprecipitated genomic
DNA fragments encompassing the region containing ETS binding sites
in the endogenous Gata4 G9 enhancer, as indicated by ampliﬁcation
with primers speciﬁc for the region (Figs. 8A, C, α-ETS1 and α-ERG).
A nonconserved region 5 kb away from the ETS binding sites was not
ampliﬁed under conditions in which the region containing ETS binding
sites in the endogenous Gata4 G9 enhancer was efﬁciently ampliﬁed
(Figs. 8B, D α-ETS1 and α-ERG), showing that anti-ETS1 and anti-ERG
antibodies were binding speciﬁcally to the ECR in Gata4 G9 and not
to adjacent non-conserved regions. Importantly, neither the ECR con-
taining the ETS binding sites nor the nonconserved region 5 kb away
were immunoprecipitated by non-speciﬁc isotype control antibody
(Figs. 8A–D, IgG). Thus, these results establish that ETS1 and ERG
bind directly to the Gata4 G9 enhancer in the ECR containing multiple
bona ﬁde essential ETS sites.
Discussion
Regulation of Gata4 expression in the heart
GATA4 is an important transcriptional regulator of myocardial and
endocardial development, and numerous studies have deﬁned its re-
quirement and downstream gene targets in those lineages (Garg et
al., 2003; Oka et al., 2006; Rivera-Feliciano et al., 2006; Rojas et al.,
2008; Zeisberg et al., 2005). However, prior to the present study, di-
rect transcriptional regulation of the Gata4 gene itself had not been
deﬁned in any cardiovascular lineage. The activity of the Gata4 G9 en-
hancer described here overlaps almost perfectly with GATA4 expres-
sion in the endocardium but, unlike endogenous GATA4 protein, it is
Fig. 7. ETS factor expression proﬁle in embryonic mouse hearts. (A) Quantiﬁcation of ETS transcript levels in embryonic hearts at E8.5 by qPCR showed that GABPA, FLI1, ETV5, ETV6,
ETS1, ERG, ELF1, ETV1, and ETS2 were the most abundant. Data are expressed as the mean transcript abundance relative to GAPDH from 5 independent tissue isolations and qPCR
analyses. Error bars represent SEM. (B–F) Immunohistochemical analyses of wild type E8.5 mouse hearts with antibodies to ETS1, FLI1, ERG, GABPA, and ETV6. FLI1, ETS1, and ERG
proteins were expressed in locations with Gata4 G9 enhancer activity (compare panels B–D with Figs. 2G–I). ETS1 and FLI1 proteins were expressed in the endocardium (asterisks
in B, C) and myocardium (arrowheads in B, C). ERG expression appeared to be largely restricted to the endocardium (asterisks in D). GABPA protein was strongly expressed in the
foregut and largely absent from the embryonic heart (E). ETV6 protein was present in the myocardium (arrowheads in F) with little or no expression detected in the endocardium
(asterisks in F). Bars in all panels=100 μM.
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al., 2006; Zeisberg et al., 2005), suggesting that other regulatory mod-
ules must control Gata4 expression in myocardial cells. To date, we
have not identiﬁed any myocardial enhancers based solely on se-
quence conservation, suggesting the Gata4 locus includes non-Fig. 8. ETS1 and ERG bind to the endogenous Gata4 G9 enhancer in aortic endothelial
cells. BAEC were used as a source of genomic material in ChIP to examine ETS1 and
ERG binding to the Gata4 G9 ECR, which contains the essential ETS sites. Input material
not subjected to ChIP was used a positive PCR control. ChIP with isotype-matched IgG
was used as negative control. Isolated genomic material was subjected to PCR, and the
resulting products were analyzed by agarose gel electrophoresis. (A, C) PCR with
primers speciﬁc to the Gata4 G9 ECR demonstrated that the region of the endogenous
bovine Gata4 G9 enhancer containing the ETS sites was bound by ETS1 (A) and ERG (C)
in vivo. (B, D) PCR with primers designed to detect a region of the bovine Gata4 locus
5 kb from the G9 enhancer shows that neither ETS1 (B) nor ERG (D) bound to this re-
gion distal to G9 under identical conditions in which G9 was bound in (A, C). Sizes in bp
are indicated at the left of each panel. H2O (water) indicates a negative PCR control
with no added template.conserved enhancer elements. Consistent with this notion, recent
work identifying enhancers by combining ChIP and deep-
sequencing demonstrated that many functional enhancers in numer-
ous cardiac genes exist outside of regions of sequence conservation
(Blow et al., 2010; Visel et al., 2009).
A recent genome-wide ChIP-seq analysis using biotinylated cardiac
transcription factors expressed in the cardiomyocyte cell line HL1 iden-
tiﬁed the Gata4 G9 region as a bound target, suggesting myocardial oc-
cupancy of the enhancer by GATA4 and myocardial-speciﬁc activation
(He et al., 2011). By contrast, our detailed analyses in transgenic mice
demonstrate that the element is predominantly endocardial, although
we observed incomplete, weak myocardial activity in a minority of
the lines at linear and looping heart stages (Figs. 2, 3). Furthermore,
mutation of GATA sites in the ECR, which were bound by GATA4 in
EMSA, did not negatively affect enhancer activity in the hearts of trans-
genic embryos at any stage examined (data not shown). Thus, it is clear
that additional approaches will be needed to fully describe the regula-
tion of Gata4 in the myocardium.
Regulation of endocardial gene expression by ETS transcription factors
ETS factors are essential regulators of endothelial-restricted gene
expression (De Val and Black, 2009), and a regulatory role in the endo-
cardium further reinforces the notion that endocardium is a specialized
endothelium (Harris and Black, 2010). Here, we analyzed the ETS tran-
script expression proﬁle in the early embryonic heart and found that
transcripts for FLI1, ETV5, ETV6, ETS1 ERG, ELF1, ETV1, and ETS2 were
the most highly expressed in the early embryonic heart (Fig. 7).
Based on our data, the ETS expression proﬁle of the embryonic heart
shares more similarities with the HUVEC proﬁle than the adult heart
proﬁle (Hollenhorst et al., 2004), suggesting distinct embryonic and
adult ETS proﬁles for the heart.
Our data support a model in which Gata4 is directly regulated by
ETS1, ERG, or both factors in the developing heart because enhancer
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hancer in BAEC. However, it is important to note that our studies do
not exclude other ETS factors as potential transcriptional regulators
nor do they prove that ETS1 and ERG regulate Gata4 in the embryonic
heart. ETS1 and ERG each play important roles in endothelial gene
regulation and function (Gao et al., 2010; Hashiya et al., 2004;
Loughran et al., 2008; Nikolova-Krstevski et al., 2009; Pham et al.,
2007; Taoudi et al., 2011; Wei et al., 2009; Ye et al., 2010), and ETS1
and ERG are expressed broadly throughout the endothelium, includ-
ing the endocardium (Fig. 7; Ye et al., 2010). The Gata4 G9 enhancer
is active only in a subset of the ETS1 and ERG expression domains,
so it is unclear how Gata4 G9 enhancer activity becomes restricted
within these domains. There are several possible explanations. It is
possible that the Gata4 G9 enhancer responds only to high ETS pro-
tein levels, as a recent study that analyzed ERG expression in different
vascular beds of the heart found that ERGwas enriched in endocardial
endothelial cells compared to venule, artery, and capillary endothelial
cells (Yuan et al., 2011). A second possibility is that additional activa-
tors expressed exclusively in the Gata4-G9-lacZ expression domain
may be required in combination with ETS factors for enhancer activa-
tion to occur. A third possibility is that the Gata4 G9 enhancer may
contain binding sites for a repressor that restricts its activity in
areas of endothelium other than endocardium. Identiﬁcation of the
mechanisms that restrict expression should help explain the long-
standing observation that endocardium is a molecularly and function-
ally unique endothelium, and future studies will address the molecu-
lar mechanisms controlling this restriction.
Origins of the endocardium
The endocardium shares many properties with other endothelial
populations, but mounting evidence suggests the endocardium is
more than just a spatially restricted subpopulation of endothelium.
Cardiovascular lineages, including endocardium, arise from multipo-
tent FLK1+ cells that are present during gastrulation (Fehling et al.,
2003; Kattman et al., 2006), and cardiogenic mesoderm leaves the
primitive streak after mesoderm fated to become other endothelial
populations has already exited (Kouskoff et al., 2005; Misfeldt et al.,
2009). Interestingly, GATA4 protein was detectable, and the Gata4 G9
enhancer was active, in the allantois (Figs. 2D–F, 4B–D), which contains
FLK1+ vasculogenic tissue (Downs et al., 1998), suggesting the endo-
cardium and allantois may share common regulatory pathways.
Using embryonic stem cells bearing an Nfatc1-lacZ BAC transgene
to track endocardial cell production, Misfeldt et al., demonstrated
that culturing ES cells with Wnt3a gave rise to endothelial cells,
while culturing ES cells with Noggin and Dickkopf-1 gave rise to en-
docardial and myocardial cells (Misfeldt et al., 2009), suggesting de-
veloping endocardium responds to cardiogenic signals. Several
studies have demonstrated the close association between endocardial
and myocardial progenitors (Kattman et al., 2006; Masino et al.,
2004) and the data presented here, that the Gata4 G9 enhancer is
brieﬂy active in both myocardial and endocardial cell types prior to
restricting to the endocardium and endocardial cushions, also sup-
ports the close relationship between endocardial and myocardial
cells.
Transcriptional pathways in congenital heart disease
Analyses of the speciﬁc mutations in human GATA4 and mecha-
nistic studies in model systems suggest that disruption of GATA4
transactivation function or interaction with other transcription fac-
tors may be the underlying reason for the defects associated with
GATA4 mutations (Garg et al., 2003; Moskowitz et al., 2011;
Schluterman et al., 2007). Together, these studies suggest that a
greater understanding of the transcription factor interactions and
pathways involving GATA4 may lead to a clearer understanding ofthe mechanisms underlying endocardially-derived heart defects.
Consistent with this idea, ETS1 mutations have also recently been
associated with endocardium-derived defects in humans (Ye et al.,
2010).
An ultimate goal of deﬁning transcriptional pathways of cardiac
development is to clarify the mechanisms underlying cardiac defects.
GATA4 mutations in humans are strongly associated with valve and
septation defects (Butler et al., 2010; Garg et al., 2003; Hirayama-
Yamada et al., 2005; Zhang et al., 2008). The valve leaﬂets and the
membranous portions of the septa are largely derived from endothe-
lial cells of endocardial origin (Harris and Black, 2010; Person et al.,
2005), suggesting that GATA4 function in endocardial derivatives is
essential for proper valve and septal development in humans. Inacti-
vation of Gata4 in endothelial cells, including the endocardium, re-
sults in embryonic lethality and profound endocardial cushion and
valve leaﬂet defects that mimic the heritable human diseases ob-
served in families with GATA4 mutations (Rivera-Feliciano et al.,
2006). Our work implicates ETS1 and ERG as direct regulators of
Gata4 via the Gata4 G9 enhancer, and as such, suggests disturbances
in ETS1 or ERG function in the endocardium could underlie cardiac
diseases. This notion is supported by the recent report that deletion
of ETS1 was observed in patients with Jacobsen syndrome, and tar-
geted disruption of Ets1 in mice led to malformations in cardiac struc-
tures derived from endocardial cells (Ye et al., 2010). It would be
interesting to determine whether mutations in other ETS factors
that are expressed in the heart, including ERG, or in ETS-dependent
noncoding regulatory regions, such as the Gata4 G9 enhancer de-
scribed in these studies, are also associated with endocardial malfor-
mations in humans.
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